This bill inserts a new section (515D) into the Federal Food, Drug, and Cosmetic Act that requires certain medical devices with user interfaces to offer equivalent nonvisual access for blind and low-vision users. It ties compliance to FDA rulemaking, directs training for manufacturers, and creates a narrow waiver process.
The rule targets devices classified as Class II or III that are cleared, authorized, or approved after the statute’s regulatory effective date and that are intended for use in the home. For manufacturers and compliance teams, the bill converts accessibility from best practice to a statutory condition of marketing for new covered devices, with enforcement through an amendment that treats noncompliant devices as adulterated under Section 501.
At a Glance
What It Does
The bill defines a nonvisual accessibility standard requiring a device’s user interface to provide blind and low-vision users access with comparable privacy, independence, and ease as sighted users. It charges HHS/FDA (the Secretary) with proposing regulations within one year and publishing a final rule within two years of enactment; the final rule becomes effective one year after publication.
Who It Affects
The rule applies to Class II and III devices that have screens or mobile apps, are intended for home use (not solely for clinicians), and receive FDA clearance, marketing authorization, or approval after the bill’s effective date. Device manufacturers, product designers, accessibility vendors, and FDA review teams will bear primary compliance responsibilities.
Why It Matters
This is a statutory shift that makes nonvisual accessibility a premarket regulatory requirement for new covered devices rather than a voluntary design choice, with a built-in training mandate and a waiver pathway narrowly framed by 'fundamental alteration' and 'undue hardship' tests.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a single, outcome-focused accessibility benchmark: a device’s user interface must enable blind and low-vision users to access information, interact with the device, and enjoy its services with comparable privacy, independence, and ease of use as sighted users. The standard is functional rather than prescriptive — it does not mandate particular technologies (text-to-speech, tactile controls, or mechanical alternatives) but instead sets parity of outcome as the statutory goal.
FDA must write regulations to implement that standard on a strict schedule: propose within one year, finalize within two years, and the final rule takes effect one year after publication. The statute also requires the agency to create training for manufacturers so they understand how to comply, and to consult with the Architectural and Transportation Barriers Compliance Board and actual blind or low-vision individuals while developing standards and training.Not every medical device is covered.
The bill limits coverage to devices in Class II or III that are cleared, granted marketing authorization, or approved after the effective date and that have a user interface (defined to include screens and mobile apps). Critically, devices intended solely for healthcare professionals or for use outside the home are excluded.
For covered devices, failure to meet the standard (or to obtain a waiver) is treated as adulteration under Section 501, which gives FDA an enforcement pathway to restrict marketing.Manufacturers can seek waivers, but the bar is high: the Secretary may waive the requirement only upon clear and convincing evidence that compliance would cause a fundamental alteration to the nature of the product or would impose an undue hardship. The statute lists factors to weigh for undue hardship (including nature and cost of compliance and a manufacturer’s financial resources) but leaves the precise application to FDA rulemaking and adjudication.
The bill thus blends a firm prescriptive timeline with flexible, case-by-case relief for exceptional circumstances.
The Five Things You Need to Know
The bill adds section 515D to the FDCA establishing an outcome-based nonvisual accessibility standard for user interfaces on covered devices.
Covered devices are Class II or III devices with a screen or mobile app, intended for home use (not exclusively for providers), and cleared/authorized/approved after the statute’s regulatory effective date.
FDA must publish proposed implementing regulations within 1 year of enactment, finalize rules within 2 years, and the final rule becomes effective 1 year after publication.
The Secretary may grant a waiver only on clear and convincing evidence that compliance would cause a 'fundamental alteration' or an 'undue hardship,' with undue-hardship factors expressly including the nature/cost of compliance and the manufacturer’s financial resources.
Beginning on the final rule’s effective date, a covered device that does not meet the nonvisual accessibility standard (or lack an approved waiver) is treated as adulterated under the FDCA’s Section 501(k), creating an enforcement trigger for FDA.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the act’s public name as the 'Medical Device Nonvisual Accessibility Act of 2025.' This is ceremonial but important for citations and for how implementing guidance and agency communications will refer to the authority.
Findings
Lists Congress’s factual findings about the rise of digital user interfaces in medical devices, the inaccessibility of many home-use products, and the potential for accessible design to reduce errors and costs. These findings frame statutory intent and will inform judicial and administrative interpretation, particularly regarding the statute’s emphasis on private, independent, and safe use by blind and low-vision consumers.
Nonvisual accessibility standard and definitions
Subsection (a) sets an outcome-oriented standard: the user interface must be 'as effective' for blind or low-vision individuals as for others, emphasizing parity in privacy, independence, and ease. Subsection (f) defines covered device elements, 'user interface' (screens or mobile apps), and key statutory terms like 'fundamental alteration' and 'undue hardship.' The definitions narrow coverage to home-use Class II/III devices cleared or approved after the statutory timelines, focusing the obligation on new market entries rather than legacy products.
Waiver, training, and stakeholder consultation
Subsection (b) creates a waiver process that allows FDA to exempt a device if the manufacturer meets the clear-and-convincing burden showing fundamental alteration or undue hardship. Subsection (c) requires the Secretary to conduct training for manufacturers on the standard and compliance pathways. Subsection (d) requires consultation with the Architectural and Transportation Barriers Compliance Board and blind/low-vision individuals while developing standards and training, embedding user-centered input into rulemaking and guidance.
Regulatory timeline and effective date
Requires the Secretary to publish proposed regulations within one year and a final rule within two years of enactment, with the final rule taking effect one year after publication. That timetable creates compressed premarket compliance planning for manufacturers who will seek clearance or approval in the months and years following enactment.
Adulteration enforcement hook (Section 501(k))
Inserts a new paragraph into Section 501 making a covered device adulterated if it fails to meet the new nonvisual accessibility standard (or lacks an FDA waiver) beginning on the final rule’s effective date. This is the statute’s primary enforcement mechanism: devices that do not comply can be subject to the FDCA’s broad enforcement tools, including injunctions, seizures, and marketing prohibitions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People who are blind or have low vision — Gain legally enforceable access to home medical devices, enabling private and independent use that statutory language explicitly protects.
- Home-based patients relying on self-administered therapies — Receive safer, more usable devices with multiple ways to confirm readings and operate equipment, which can reduce errors and emergency interventions.
- Accessibility technology vendors and integrators — See new demand for screen readers, voice interfaces, tactile solutions, and testing services as manufacturers incorporate nonvisual features earlier in design.
- Patient advocates and disability organizations — Obtain a statutory lever to press for inclusive design through rulemaking, stakeholder consultation, and enforcement pathways.
Who Bears the Cost
- Medical device manufacturers (especially those making Class II/III home-use products) — Must design, test, and document nonvisual accessibility features for new products and may face higher development and regulatory submission costs.
- Small and mid-sized device firms — Face proportionally larger compliance burdens; the statutory 'undue hardship' test may provide relief, but proving it requires litigation-grade evidence and potentially costly procedures.
- FDA (the Secretary) and its review centers — Must allocate staff and resources to write technical regulations, run training, evaluate waiver requests that use a high evidentiary standard, and incorporate accessibility review into premarket evaluation.
- Third-party testing and conformity-assessment bodies — Will be called on to develop new protocols and testing services to verify nonvisual accessibility, adding responsibilities and costs in a nascent market.
Key Issues
The Core Tension
The bill forces a choice between enforcing equal access to life-sustaining home medical technology and imposing potentially substantial design and regulatory costs on device makers; achieving meaningful nonvisual usability may require design changes that some manufacturers claim alter device function or impose undue hardship, but denying access perpetuates safety and equity harms for blind and low-vision users.
The bill sets an outcome-based standard rather than technology mandates, which gives FDA flexibility but also shifts technical burden onto manufacturers and reviewers to translate parity into measurable test criteria. That translation will determine whether compliance is practical across varied device categories (from blood pressure cuffs to in-home infusion pumps).
The statutory waiver route is legally significant but vague: 'clear and convincing evidence' is a high bar and the undefined contours of 'fundamental alteration' invite litigation over whether accessibility changes would impair essential device functions.
The regulatory timetable compresses rulemaking and compliance planning into a three-year window (1 year to propose, 2 to finalize, plus a 1-year effective lag). Manufacturers planning near-term submissions will need to decide whether to design to anticipated standards or seek waivers, creating business uncertainty.
The statute exempts devices intended solely for providers or for non-home settings, which could incentivize manufacturers to change labeling or intended-use claims to avoid the requirement. Finally, integrating nonvisual access raises secondary issues—cybersecurity of voice interfaces, intellectual property concerns around UI disclosure, and interoperability with third-party assistive technologies—that the bill does not resolve and that FDA rulemaking will need to address.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.